Intra-Cavernosal Injection of Botulinum Toxin in the Treatment of Erectile Dysfunction: a Systematic Review and Meta-Analysis.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of clinical studies
PubMed 36115427 · doi:10.1016/j.urology.2022.08.039
What was done
Authors conducted a systematic review and meta-analysis of PubMed, Embase, and Medline databases from January 1990 through July 31, 2021, examining intracavernosal injection of botulinum toxin (BoNT-A) for erectile dysfunction. Seven studies were included in the review, including two pre-clinical studies. Meta-analysis was performed on three outcomes reported across at least two studies: Peak Systolic Velocity in the cavernosal artery (PSV), Erection Hardness Score (EHS), and Sexual Health Inventory for Men (SHIM) score.
What was found
Intracavernosal BoNT-A showed a statistically significant improvement in PSV (mean difference [MD] 10.82, 95% CI [4.99, 16.65], I2 = 61%) and EHS compared to placebo (MD 0.70, 95% CI [0.47, 0.93], I2 = 94%). However, no statistically significant difference was found for SHIM scores (MD 0.58, 95% CI [-0.03, 1.20], I2 = 85%).
Why it matters
While intracavernosal botulinum toxin is being explored as an alternative to invasive surgery for erectile dysfunction, current pooled evidence shows physiological improvements in vascular flow and hardness without a clear patient-reported functional benefit on SHIM scores.
Limits
The total evidence base is small (seven total studies, two of which were pre-clinical). Meta-analyzed outcomes had substantial to extreme heterogeneity (I2 ranging from 61% to 94%). Total patient sample sizes, specific trial control designs, dosing schedules, follow-up durations, and safety data were not reported in the abstract.
Cited by
- supports Botox injections into sexual organs relax muscle tissue and improve vascularity.